Hanmi Pharm. Co. Ltd.
- Address
- 14 Wiryeseongdae-Ro
Sponsor Overview
Specializations
Endocrine and Metabolic Disorders
Hanmi Pharm. Co. Ltd. is active in clinical research on congenital hyperinsulinism, with a focus on pediatric patients affected by abnormal insulin regulation and recurrent hypoglycemia. Its work in this area centers on therapies intended to address the underlying metabolic instability associated with this rare endocrine condition.
- Congenital Hyperinsulinism
- Pediatric endocrinology
- Glucose homeostasis
The sponsor’s research interest in this field reflects a therapeutic emphasis on rare metabolic diseases requiring specialized clinical management.
Gastrointestinal and Intestinal Failure
The company also supports studies in short bowel syndrome-associated intestinal failure, a severe gastrointestinal disorder marked by impaired nutrient absorption and dependence on complex supportive care. This area of interest includes treatment approaches aimed at improving intestinal function in patients with compromised bowel length or absorption capacity.
- Short Bowel Syndrome-associated Intestinal Failure
- Intestinal absorption disorders
- Gastroenterology
Its clinical portfolio in this domain is directed toward conditions with significant nutritional and gastrointestinal burden.
Pediatric Therapeutic Development
Hanmi Pharm. Co. Ltd. is involved in research involving pediatric patients across both rare disease areas, highlighting a therapeutic interest in age-specific treatment needs. The sponsor’s studies address conditions that require careful evaluation in children, particularly where long-term disease control and tolerability are central clinical concerns.
- Pediatric medicine
- Rare disease care
- Long-term treatment tolerability
This focus places emphasis on medical areas where child-centered therapeutic options remain limited.
Clinical Pharmacology and Drug Safety
Across its funded trials, the sponsor places attention on safety, tolerability, and pharmacokinetics, indicating a strong clinical pharmacology component in its research activity. These areas are relevant to assessing how investigational therapies behave in the body and how well they are tolerated in patients with rare disorders.
- Safety assessment
- Tolerability evaluation
- Pharmacokinetic profiling
Its studies align with therapeutic development in rare diseases where treatment characterization is essential.
Sponsored Trials
| Trial Name | Country | Status |
|---|---|---|
| Evaluation of Safety, Tolerability, Pharmacokinetics, and Activity of Efpegerglucagon in Pediatric Patients with Congenital Hyperinsulinism |  Germany | Recruiting |
| Evaluation of Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of HM15912 in Adults with Short Bowel Syndrome-associated Intestinal Failure |  Belgium Denmark France Germany Poland | Recruiting |
Data & Insights
This sponsor works with 2 molecules, of which 2 are not being studied by other sponsors.
This sponsor has worked with 12 sites across their trial portfolio.
Therapeutic Focus
- 1.Digestive System Diseases1 trial280 other sponsors
- 2.Nutritional and Metabolic Diseases1 trial211 other sponsors
Partnered Research Centres
12 centres- Address
- Moelleparkvej 4, 9000 Aalborg
- Address
- Lohmuehlenstrasse 5, St. Georg, 20099 Hamburg
- Address
- 165 Chemin Du Grand Revoyet, 69310 Pierre Benite
- Address
- 1 Rue Jean Burguet, 33000 Bordeaux
- Address
- 151 Route De Saint Antoine, 06200 Nice
- Address
- 100 Boulevard Du General Leclerc, 92110 Clichy
Want to get in touch with this sponsor?
Send a question and we'll pass it on to Hanmi Pharm. Co. Ltd..
Need a custom report on this sponsor?
Competitive positioning, market entry, partnership opportunities — tell us the question.
Is something out of date?
Tell us what needs correcting and we'll update this profile.